5 completed, 1 recruiting. 6 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Completed 5, Recruiting 1 |
| Phase 1 | 1 | Completed 1 |
Follow dotinurad: new trials by email Literature Review of dotinurad trials Research Report on dotinurad
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 2 Trial of Dotinurad in Xanthine Oxidase Inhibitor (XOI) Intolerant/Uricase Failure Gout Participants Dotinurad, Placebo - Gout | Phase 2 | Recruiting | Crystalys Therapeutics | 90 | 2026-05-08 | 2026-09-28 |
| Open Label PK, PD and DDI of Dotinurad and Allopurinol in Gout Patients With Hyperuricemia dotinurad, dotinurad + allopurinol, allopurinol - Gout, Hyperuricemia | Phase 1 / Phase 2 | Completed | Urica Therapeutics Inc. | 20 | 2023-10-04 | 2026-06-10 |
| Study of FYU-981 in Hyperuricemia (Effect on Two Hyperuricemic Types) FYU-981, Topiroxostat - Hyperuricemia | Phase 2 | Completed | Fuji Yakuhin Co., Ltd. | 24 | 2016-07-01 | 2018-08-21 |
| Clinical Pharmacology of FYU-981 (Effect on QT/QTc Interval) FYU-981, Placebo, Moxifloxacin - Healthy | Phase 2 | Completed | Fuji Yakuhin Co., Ltd. | 48 | 2015-08-01 | 2017-09-08 |
| Study of FYU-981 in Hyperuricemia With or Without Gout FYU-981, Placebo - Hyperuricemia | Phase 2 | Completed | Fuji Yakuhin Co., Ltd. | 200 | 2015-05-01 | 2017-02-14 |
| Study of FYU-981 in Hyperuricemia With or Without Gout FYU-981 High dose, (Oral daily dosing for 8 weeks), FYU-981 Middle dose, (Oral daily dosing for 8 weeks), FYU-981 Low dose, (Oral daily dosing for 8 weeks) - Hyperuricemia | Phase 2 | Completed | Fuji Yakuhin Co., Ltd. | 80 | 2014-01-01 | 2015-01-26 |
Hyperuricemia (4) · Gout (2)
Fuji Yakuhin Co., Ltd. (4) · Crystalys Therapeutics (1) · Urica Therapeutics Inc. (1)
Japan (4) · United States (2)